Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Public Service and the Rheumatologist

Bruce N. Cronstein, MD  |  Issue: August 2007  |  August 1, 2007

Bruce N. Cronstein, MD

From jury duty to hospital committees, our institutions depend on the people of this country for community and public service. Although trying and often time consuming, this service is usually provided in good humor and with the best of intentions. Unfortunately, community service has recently earned a less lofty reputation. As punishment for miscreants, community service follows right after sincere regrets and rehabilitation for substance abuse in the “stations of the celebrity.” As documented in the news reports, for students applying for admission to top colleges, “voluntary” community service is no less a formal requirement than good grades or SAT scores.

Certain forms of community service can be onerous but I often take pleasure in jury duty despite the time imposition. The joy is not due to just the proximity of Chinatown and its delightful restaurants to the courts in Manhattan. It is interesting to see professionals of a different sort work and take part in a process that is critical to the proper functioning of civil society. Similarly, the drudgery of committee work at my medical center has its gratifications: the satisfaction of a job well done and the sense that the commonweal has been served are their own form of recompense. Needless to say, I get a lot of this sort of satisfaction.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Letters to the the Editor: Feedback from our Readers

I enjoyed Dr. Cronstein’s recent article about pharma and CME [“Cost of a Free Lunch,” May 2007, p.4], but wondered if he or others had comments regarding the equally (or more?) disturbing issue of our own “colleagues” traveling hither and yon across the country at the behest (and reward) of pharma to educate clinicians about various therapies – including some (i.e., anti-TNF inhibitors) that have been around for a while. Don’t meetings and publications provide the same information for us? Should primary care physicians be prescribing these medications at all? Talk about influence and marketing….

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Paul H. Waytz, MD, Rheumatologist, Private Practice Arthritis and Rheumatology Consultants, Minneapolis, Minn.

To Serve or Not To Serve?

However, my ambivalence to the claims of public service was recently reinforced by an event that has left me troubled. Several months ago, I was asked to serve on the advisory committee of the Food and Drug Administration (FDA) that was tasked with reviewing the evidence for approval of a new COX2 inhibitor (Arcoxia) from Merck. When initially invited to serve on this committee, I did not think that I had any conflicts of interest. I had spoken for Merck five or six years ago and edited a Web site sponsored by Merck that went under four or five years ago. Since then, I had had little contact with the company.

Page: 1 2 3 | Single Page
Share: 

Filed under:Legislation & Advocacy Tagged with:AdvocacyEditorials/commentary from experts

Related Articles

    Drug Updates: Information on New Approvals and Medication Safety

    January 1, 2010

    Information on New Approvals and Medication Safety

    New ACR/ARP Committee Members Are Ready to Work

    January 16, 2020

    Volunteering is a great way to give back and can be truly meaningful. Myriad worthwhile causes exist, so it can be hard to choose among them, but donating time to ACR and ARP committees helps promote rheumatology practice and brings awareness to rheumatic diseases. The College relies on volunteers to help achieve strategic priorities, promote…

    Zombie Therapies: Ivermectin & COVID-19

    March 14, 2022

    He just didn’t get it. I love my mechanic. After many years of taking my car to mechanics who took my money without explaining what they were doing with it, I finally found someone who loved to teach. Whenever I bring my car to his shop, class is in session. He gestures for me to…

    Drug UPDATES

    January 17, 2011

    Information on New Approvals and Medication Safety

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences